Table 2 Indications for surgery, type of PRF, and method of fixation
Author (year) | Type of implant | Fixation | No. of previous surgery (range) | Primary Fx (rate) | Periprosthetic Fx (range) | AL (rate) | PJI (rate) | Other |
|---|---|---|---|---|---|---|---|---|
Malkani et al. [17] | Monobloc | N/A | N/A | 15 (30%) | 3 (6%) | 26 (52%) | 0 (0%) | 6 (12%) [5 Girdlestone, 1 arthrodesis] |
Haentjens et al. [18] | (Protek A.G., Berne, CH) | Cemented | (1-6) | 0 (0%) | 0 (0%) | 19 (100%) | 0 (0%) | 0 (0%) |
Parvizi et al. [3] | MRS (Stryker Orthopaedics, Mahwah, NJ, US) | Cemented | 2.7 (0-8) | 1 (2%) | 20 (42%) | 13 (27%) | 13 (27%) | 0 (0%) |
Shih et al. [19] | Custom-made (United Ustar System, Taipei, Taiwan) | Cemented | 6.5 (3-22) | 0 (0%) | 3 (23%) | 3 (23%) | 9 (70%) | 0 (0%) |
Schoenfeld et al.[20] | Modular PFR (Howmedica, Allendale, NJ; Biomet, Warsaw, IN, US) | Cemented | N/A | 21 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Bertani et al. [21] | JVC-IX (Wright Medical Technology Inc., Arlington, TN, US) | Cemented | N/A | 2 (20%) | 0 (0%) | 8 (80%) | 0 (0%) | 0 (0%) |
Gebert et al. [22] | MUTARS (Implantcast GmbH, Buxtehude, DE) | Cemented (3), Cementless (42) | N/A | 0 (0%) | 9 (20%) | 19 (42%) | 16 (36%) | 0 (0%) |
Sewell et al. [23] | METS (Stanmore Implants worldwide Ltd, Stanmore, UK) | Cemented (2), Cementless (13) | 2.8 (1-4) | 0 (0%) | 2 (13%) | 3 (20%) | 9 (60%) | 1 (7%) [Painful excision arthroplasty] |
Al Taki et al. [4] | MRS (Stryker Orthopaedics, Mahwah, NJ, US) | Cemented (33), Cementless (3) | 2 (1-5) | 0 (0%) | 27 (43%) | 27 (43%) | 7 (13%) | 2 (3%) [Instability + bone loss] |
McLean et al. [24] | GMRS (Stryker Inc., Mahwah, NJ, US) | Cemented | N/A | 4 (20%) | 9 (45%) | 0 (0%) | 7 (35%) | 0 (0%) |
Dean et al. [25] | METS (Stanmore Implants worldwide Ltd, Stanmore, UK) | N/A | 3.1 (1-11) | 8 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Colman et al. [26] | Modular Endoprosthetic PFR | N/A | N/A | 0 (0%) | 21 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
Lundh et al. [27] | METS (Stanmore Implants worldwide Ltd, Stanmore, UK) | Cemented (3), Cementless (2) | N/A | 0 (0%) | 5 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
Grammatopoulos et al. [28] | METS (Stanmore Implants worldwide Ltd, Stanmore, UK) | Cemented | 2.4 (0-17) | 12 (15%) | 16 (20%) | 6 (8%) | 40 (50%) | 4 (5%) [Instability + pseudotumor] |
Viste et al. [29] | GMRS (Stryker Inc., Mahwah, NJ, US) | Cemented | 2 (1-10) | 0 (0%) | 15 (34%) | 16 (36%) | 12 (27%) | 1 (2%) [Instability] |
Fenelon et al. [30] | GMRS (Stryker Inc., Mahwah, NJ, US); LPS (DePuy Synthes, Warsaw, IN, US) | N/A | 1.4 (0-10) | 2 (2.5%) | 50 (63%) | 9 (11%) | 5 (6.3%) | 13 (16.4%) [2 Instability, 2 Osteoarthritis, 9 Osteosynthesis failure] |
De Martino et al. [43] | GMRS (Stryker Inc., Mahwah, NJ, US) | Cemented (37), Cementless (4) | 3.6 (1-11) | 0 (0%) | 7 (17%) | 14 (34%) | 17 (42%) | 3 (7%) [Nonunion] |
Dieckmann et al. [32] | MUTARS (Implantcast GmbH, Buxtehude, DE) | Cemented | 2.5 | 0 (0%) | 0 (0%) | 0 (0%) | 49 (100%) | 0 (0%) |
Total | - | - | 3.0 (0-22) | 65 (10.3%) | 187 (29.7%) | 163 (25.9%) | 184 (29.3%) | 30 (4.8%) |